Progenics Pharmaceuticals, an oncology company developing medicines and imaging analysis technology for targeting and treating cancer, has acquired a Somerset, NJ manufacturing facility for Azedra (iobenguane I 131) for $8 million. Azedra is the first and only FDA-approved radiopharmaceutical indicated for the treatment of pheochromocytoma and paraganglioma, ultra-rare cancers.   The Somerset site serves as the launch facility for Azedra and will also provide manufacturing support for the compan...